Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 3, 2024BMC Infectious DiseasesOpen Access

Reduction in ACE2 expression in peripheral blood mononuclear cells during COVID-19 – implications for post COVID-19 conditions

View Full Paper
Ask AI
Bookmark
Share

Authors

GAGulrayz AhmedYAYasir AbdelgadirAAAmro Abdelghani

Discussion

Loading...

Member takes

Overview

Case-control study reveals suppressed PBMC ACE2 expression in severe COVID-19, suggesting combined vascular and fibrotic pathways contribute to long-term post-viral conditions.

Key Points

  • Angiotensin converting enzyme 2 expression was rarely detected in peripheral blood mononuclear cells during severe infection, with rapid recovery following convalescent plasma.
  • Severe infection yielded an odds ratio of 12.4 for undetected cellular ACE2, while plasma markers TIMP-1, PIIINP, and MMP-9 rose across 48 hospitalized patients and 72 controls.
  • Comparative analysis using RT-PCR assays and immunoassays highlights intersecting vasculopathy and renin-angiotensin system pathways as potential drivers of post-COVID-19 conditions.

Cite This Study

Ahmed et al. (2024) studied this question.

synapsesocial.com/papers/68e6180bb6db6435875aacc6https://doi.org/10.1186/s12879-024-09321-0
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1ACE2 expression in PBMC and plasma markers of vasculopathy and fibrosis during early COVID – implications for post-COVID conditions2023
  2. 2Plasma ACE and ACE2 Levels Are Altered in Patients with COVID-192026
  3. 3Expression of ACE2, Soluble ACE2, Angiotensin I, Angiotensin II and Angiotensin-(1-7) Is Modulated in COVID-19 Patients2021 · 105 citations
  4. 4#2395 Elevated circulating ACE2 activity is related with a major COVID-19 severity2024
  5. 5ACE2 Expression and Clinical Biomarkers in COVID‐19: Associations With Disease Severity2026